In March 2026, We performed 80 endometriosis surgeries. learn more > We performed 80 endometriosis surgeries. In March 2026, We performed 80 endometriosis surgeries. learn more >

Home > Gastroenterology >Fatty Liver Disease (NAFLD)

Fatty Liver Disease (NAFLD)

Fatty liver disease - medically termed NAFLD (Non-Alcoholic Fatty Liver Disease) or MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) under the newer international nomenclature - is now the most common chronic liver disease in the world, driven by the twin epidemics of obesity, Type 2 diabetes, and metabolic syndrome.

In India, fatty liver affects an estimated 9–32% of the population - with urban populations and South Asian individuals facing disproportionate risk due to the genetic predisposition to visceral adiposity and insulin resistance at lower BMI than Western populations.

NAFLD ranges from simple hepatic steatosis (fat accumulation in the liver without inflammation, which is largely benign) to NASH - Non-Alcoholic SteatoHepatitis - where active inflammation and hepatocellular injury drive progressive fibrosis toward cirrhosis and hepatocellular carcinoma.

At Shree Hospitals Ghatkopar East, we provide comprehensive fatty liver assessment, non-invasive fibrosis staging, and a structured metabolic management programme that is the most effective intervention available.

(24×7 Emergency Care)

1800-268-4000

Our Approach

How to Identify Fatty Liver Disease (NAFLD)?
FAQs
Treatments at Shree Hospitals
Specialist Doctors

(24×7 Emergency Care)

1800-268-4000

Our Approach in Managing Fatty Liver Disease (NAFLD)

NAFLD management at Shree Hospitals is structured around five steps: moving from the initial "fatty liver" ultrasound report through accurate disease characterisation, non-invasive fibrosis staging, identification of NASH versus simple steatosis, implementation of evidence-based metabolic therapy, and long-term monitoring for fibrosis progression and HCC surveillance in patients with advanced disease.

Step 1 - Beyond the Ultrasound Report: Accurate Disease Characterisation

An ultrasound report of "fatty liver" or "hepatic steatosis" is the starting point - not the diagnosis. Ultrasound confirms fat deposition in the liver when the liver echogenicity exceeds that of the right kidney and spleen, but it cannot quantify fat content accurately, cannot grade inflammation, cannot stage fibrosis, and cannot distinguish NASH from simple steatosis.

At Shree Hospitals, every patient referred with fatty liver on ultrasound undergoes complete characterisation: liver function tests (ALT, AST, GGT, bilirubin, albumin, INR), FBC (platelets), fasting glucose, HbA1c, lipid panel, thyroid function, and metabolic syndrome assessment.

Metabolic risk factors - obesity, Type 2 diabetes or pre-diabetes, hypertriglyceridaemia, hypertension - are characterised comprehensively, as NAFLD is the hepatic manifestation of metabolic syndrome and its severity correlates with the degree of metabolic dysregulation.

Secondary causes of fatty liver - significant alcohol use (above 10 units/week in women, 14 in men), drug-induced hepatic steatosis (tamoxifen, amiodarone, steroids), thyroid dysfunction, and total parenteral nutrition - are excluded before NAFLD is confirmed.

Step 2 - Non-Invasive Fibrosis Staging: Fibroscan and FIB-4

The critical question in NAFLD is not the presence of fat - it is the presence and degree of fibrosis, because fibrosis stage is the strongest independent predictor of liver-related mortality in NAFLD.

Simple steatosis without fibrosis carries excellent prognosis; NASH with F3–F4 fibrosis carries substantial risk of cirrhosis and HCC. Fibroscan (transient elastography) provides liver stiffness measurement (fibrosis staging) and CAP score (hepatic fat quantification) simultaneously.

In NAFLD, liver stiffness thresholds for fibrosis are slightly higher than for hepatitis C: F3 fibrosis approximates 9.6–12 kPa; F4 (cirrhosis) approximates above 13.6 kPa. The FIB-4 index - (Age × AST) / (Platelets × √ALT) - provides a validated non-invasive fibrosis estimate: below 1.3 = low risk; 1.3–2.67 = intermediate (requires Fibroscan); above 2.67 = high risk. The combination of FIB-4 and Fibroscan accurately stages the majority of NAFLD patients without biopsy.

Step 3 - Distinguishing NASH from Simple Steatosis

Simple steatosis - fat in the liver without active inflammation or hepatocyte ballooning - has an excellent prognosis: it progresses to significant fibrosis in less than 5% of patients over 10 years. NASH - defined histologically by the combination of steatosis, lobular inflammation, and hepatocyte ballooning with or without fibrosis - progresses to cirrhosis in 15–25% of patients and to HCC.

The NAFLD Activity Score (NAS) quantifies NASH histologically: steatosis (0–3) + lobular inflammation (0–3) + hepatocyte ballooning (0–2); NAS ≥5 indicates definite NASH. Liver biopsy remains the gold standard for NASH diagnosis but is invasive and not required in all patients.

Non-invasive NASH surrogates - elevated ALT/AST ratio, elevated ferritin, clinical metabolic syndrome, Fibroscan liver stiffness elevation, and the Enhanced Liver Fibrosis (ELF) panel - identify patients at high NASH probability who require more intensive management without biopsy.

Step 4 - Lifestyle Therapy: The Primary and Most Effective NAFLD Treatment

Weight loss is the most effective treatment for NAFLD at any fibrosis stage. A 7–10% reduction in body weight achieves histological improvement in NASH - reducing steatosis, lobular inflammation, hepatocyte ballooning, and even fibrosis regression in a proportion of patients - in multiple randomised controlled trials.

Mediterranean diet - high in olive oil, legumes, whole grains, fish, and vegetables; low in red meat, refined carbohydrates, and sugar - is the most evidence-based dietary pattern for NAFLD and is readily adaptable to Indian cooking.

Elimination of fructose-containing beverages (cold drinks, packaged juices, energy drinks, packaged flavoured dairy) produces rapid hepatic fat reduction.

Aerobic exercise - 150–200 minutes per week of moderate-intensity activity - reduces hepatic fat independently of weight loss and improves insulin sensitivity. At Shree Hospitals, weight loss counselling, dietitian-led dietary intervention, and exercise prescription are provided as integrated components of NAFLD management.

Step 5 - Pharmacological Therapy and Emerging Agents

No pharmacological agent was licensed specifically for NAFLD/NASH until March 2024, when resmetirom (Rezdiffra) - a liver-targeted thyroid hormone receptor-beta agonist - received FDA approval for NASH with fibrosis stages F2–F3, based on the MAESTRO-NASH trial showing significant fibrosis improvement at 52 weeks compared with placebo. This represents a landmark in NAFLD pharmacotherapy.

In patients with co-existing Type 2 diabetes, GLP-1 receptor agonists - particularly semaglutide (Ozempic, Wegovy) - produce significant hepatic fat reduction, ALT normalisation, and in the NASH4 trial (semaglutide 2.4mg) a significant increase in NASH resolution. Pioglitazone (thiazolidinedione) reduces hepatic inflammation and NAS score in patients with biopsy-proven NASH.

Vitamin E (800 IU/day) reduces NASH histological activity in non-diabetic patients (PIVENS trial) but is not used in diabetics or patients with prostate cancer risk.

Bariatric surgery - Roux-en-Y gastric bypass or sleeve gastrectomy - produces the most dramatic and sustained weight loss (>30%) and achieves histological NASH resolution and fibrosis regression in the majority of eligible patients.

Happy Patients & Their Case Stories

"I was told I had 'fatty liver' on ultrasound for three years and no one did anything about it. Shree Hospitals did a Fibroscan and found F3 fibrosis. That woke me up. I lost 9 kg, changed my diet completely, and my Fibroscan at one year showed improvement to F2."

Mr. Rajan M.

"My fatty liver came up on a health check and I was diabetic. Shree Hospitals started me on semaglutide for the diabetes and the hepatologist monitored my liver. My ALT normalised at 6 months and my Fibroscan improved."

Mrs. Priya S.

How To Identify Fatty Liver Disease (NAFLD)?

NAFLD is almost universally asymptomatic in its early and moderate stages - the vast majority of patients with hepatic steatosis and even early NASH have no symptoms whatsoever and are diagnosed incidentally.

The most common route to diagnosis is an abdominal ultrasound performed for an unrelated reason - abdominal pain, routine health check, or infertility workup - that reports "hepatomegaly with increased echogenicity consistent with fatty infiltration."

Abnormal liver function tests on a routine health screen - elevated ALT or GGT, sometimes with normal AST - are the second most common incidental finding that leads to NAFLD investigation.

When symptoms do occur, they are non-specific and easily attributed to other causes: persistent fatigue and tiredness disproportionate to activity, a vague sense of heaviness or discomfort in the right upper abdomen (from hepatomegaly), and reduced exercise tolerance.

These symptoms do not distinguish NAFLD from any other cause of fatigue and should not be relied upon as diagnostic indicators.

Patients with the metabolic syndrome cluster - central obesity, Type 2 diabetes or pre-diabetes, hypertriglyceridaemia, low HDL cholesterol, and hypertension - have the highest NAFLD prevalence and should be screened systematically, as NAFLD is the hepatic component of the metabolic syndrome.

Lean NAFLD - The South Asian Clinical Challenge:

A clinically important and distinctly Indian phenomenon is lean NAFLD - fatty liver and NASH occurring in individuals with normal or near-normal BMI (below 23 kg/m²).

South Asian and East Asian populations develop visceral adiposity and hepatic fat at lower BMI than Western populations due to the thin-fat phenotype: relatively low skeletal muscle mass combined with high visceral fat deposition producing insulin resistance at a lower absolute body weight.

Genetic variants - PNPLA3 I148M and TM6SF2 E167K - that increase hepatic fat accumulation and NASH risk are more prevalent in South Asian populations.

These lean NAFLD patients are missed by BMI-based obesity screening and require metabolic assessment - waist circumference, visceral fat estimation, insulin resistance markers - to identify NAFLD risk despite a "normal" body weight.

Important FAQs: Fatty Liver Disease (NAFLD)

Is fatty liver dangerous or can I ignore it?

Whether fatty liver requires active management depends on the stage of disease. Simple steatosis - fat in the liver without inflammation - has an excellent prognosis and progresses to significant fibrosis in fewer than 5% of patients over 10 years. However, NASH - the active inflammatory form with hepatocyte ballooning and lobular inflammation - progresses to cirrhosis in 15–25% of patients and represents a genuine long-term liver cancer risk. The critical problem is that ultrasound cannot reliably distinguish simple steatosis from NASH, and NASH cannot be reliably identified on symptoms alone because it is typically asymptomatic. "Fatty liver" reported on ultrasound requires non-invasive fibrosis staging - at minimum, FIB-4 calculation and ideally Fibroscan - to determine whether the underlying disease is progressive or benign. Ignoring it entirely without staging investigation is not appropriate clinical management.

Can fatty liver be reversed with diet?

Yes - hepatic steatosis (fat in the liver) is reversible with sustained dietary change and weight loss. The liver is a highly dynamic organ that rapidly reduces fat content in response to caloric restriction and weight loss. Studies using MRI-PDFF (the most accurate non-invasive hepatic fat measurement) demonstrate significant fat reduction within 8–12 weeks of a caloric deficit diet, even before substantial body weight change. A 7–10% reduction in body weight achieves histological improvement in NASH - including reduction in the NAFLD Activity Score and, importantly, fibrosis regression - in multiple RCTs. Early-stage fibrosis (F1–F2) is more reversible with weight loss than established F3–F4 fibrosis. The Mediterranean diet, low-GI carbohydrate eating patterns, and elimination of fructose-containing beverages produce the most consistent and clinically significant hepatic fat reduction.

I am not overweight but was told I have fatty liver. How is that possible?

Lean NAFLD - fatty liver occurring in individuals with normal BMI - is an important and underdiagnosed phenomenon that is particularly prevalent in South Asian populations. Indian, Pakistani, and Sri Lankan individuals develop visceral adiposity, insulin resistance, and hepatic fat at BMI levels well below the Western obesity threshold of 30 kg/m². A South Asian person with BMI 22 kg/m² can have the visceral fat volume and metabolic risk profile of a European person with BMI 28–29. The genetic variants PNPLA3 I148M and TM6SF2 E167K - which increase hepatic fat accumulation and NASH risk - are more prevalent in South Asian populations. Assessment of lean NAFLD patients focuses on metabolic markers rather than BMI: waist circumference, insulin resistance (HOMA-IR), fasting triglycerides, ALT/AST ratio, and Fibroscan - all of which can be abnormal in a lean individual with significant NASH.

Does alcohol cause fatty liver? Am I an alcoholic if I have NAFLD?

NAFLD by definition occurs in the absence of significant alcohol use — the diagnostic threshold for "significant" alcohol use is currently above 10 standard units per week in women and 14 units per week in men. NAFLD is caused by metabolic factors — insulin resistance, obesity, Type 2 diabetes, dyslipidaemia — not by alcohol. Alcoholic fatty liver disease (ALD) is a separate entity caused by alcohol hepatotoxicity. The distinction matters for management: NAFLD is treated by metabolic risk factor control; ALD is treated by abstinence. However, in patients with NAFLD, even moderate alcohol consumption (well below the ALD threshold) appears to accelerate fibrosis progression by adding a second hepatic insult to the metabolic injury — and alcohol cessation or minimisation is advised in all NAFLD patients with significant fibrosis.

Does fatty liver cause liver cancer?

NAFLD - particularly NASH with advanced fibrosis - is now one of the leading causes of hepatocellular carcinoma (HCC) globally, and the fastest-growing indication for liver transplantation in Western countries. NASH cirrhosis carries an annual HCC incidence of approximately 1–2.6% - equivalent to HCV-related cirrhosis. More concerning, HCC in NAFLD occasionally arises in patients with advanced fibrosis (F3) who have not yet reached established cirrhosis - a phenomenon not well-recognised with other liver disease aetiologies. All NAFLD patients with F3–F4 fibrosis or established cirrhosis at Shree Hospitals are enrolled in 6-monthly HCC surveillance with liver ultrasound and AFP. Patients with F1–F2 fibrosis are monitored annually with Fibroscan - if fibrosis progresses, HCC surveillance is initiated.

Will I need a liver transplant because of NAFLD?

The majority of NAFLD patients - even those with NASH - will not require liver transplantation. Progression to cirrhosis occurs in 15–25% of NASH patients, and progression to decompensated cirrhosis requiring transplant represents a further subset of this group. However, NASH is now the second most common indication for liver transplantation in the United States (after alcohol-related liver disease), and the trajectory in India is similar given the NAFLD epidemic. The most powerful intervention to prevent NAFLD progression to transplant-level disease is achieved at the F1–F2 stage - when 7–10% weight loss produces the most substantial fibrosis regression. By the time F4 cirrhosis develops, reversibility is limited and the focus shifts to preventing decompensation and HCC.

Treatments for Fatty Liver Disease (NAFLD)

Fibroscan, CAP Score & Non-Invasive NAFLD Staging

At Shree Hospitals, FibroScan measures liver stiffness and fat content (CAP score) in a quick, non-invasive test. FIB-4 is also used to assess fibrosis risk. Patients needing more precise fat measurement may undergo MRI-PDFF, a highly accurate non-invasive method for assessing liver fat.

Structured Weight Loss & Mediterranean Dietary Programme

At Shree Hospitals, NAFLD management focuses on supervised weight loss, diet, and exercise. A personalised Indian diet plan targets excess calories, refined carbohydrates, fructose, and processed foods. The goal is 7–10% weight loss over 6–12 months, supported by regular aerobic and resistance exercise.

Pharmacological NASH Treatment - GLP-1 Agonists, Pioglitazone & Resmetirom

For NASH with significant fibrosis (F2–F3), medicines may be added when lifestyle changes alone are insufficient. Depending on the patient’s condition, options may include GLP-1 receptor agonists, pioglitazone, or resmetirom, alongside continued diet, exercise, and weight management.

Advanced NAFLD Monitoring - HCC Surveillance & Cirrhosis Management

Patients with advanced NAFLD fibrosis or cirrhosis require regular monitoring for complications. At Shree Hospitals, this may include 6-monthly liver ultrasound with AFP, upper endoscopy for varices, FibroScan, and liver function tests. Controlling blood sugar, cholesterol, blood pressure, and weight also helps slow disease progression.